Search Result

Results for "

Fatty acid amide hydrolase

" in MedChemExpress (MCE) Product Catalog:

標的別:	Epoxide Hydrolase (1) FAAH (49) 5-HT Receptor (1) Apoptosis (1) Autophagy (16) Bacterial (1) Biochemical Assay Reagents (2) Cannabinoid Receptor (3) Ceramidase (3) Drug Intermediate (1) Endogenous Metabolite (9) Fluorescent Dye (1) Fungal (1) Glutathione Peroxidase (2) Histamine Receptor (1) Influenza Virus (1) Interleukin Related (1) MAGL (8) Nucleoside Antimetabolite/Analog (2) Potassium Channel (1) Reactive Oxygen Species (ROS) (1) Reference Standards (6) SARS-CoV (3) Thyroid Hormone Receptor (1) TRP Channel (2) Tyrosine Hydroxylase (1) Virus Protease (2)
研究分野別:	Cancer (7) Cardiovascular Disease (1) Endocrinology (1) Infection (4) Inflammation/Immunology (9) Metabolic Disease (20) Neurological Disease (27)
クリックケミストリー:	Alkynes (1)

阻害剤およびアゴニスト

蛍光色素

生化学アッセイ試薬

天然物

クリックケミストリー

Targets Recommended: FAAH Epoxide Hydrolase Free Fatty Acid Receptor Fatty Acid Synthase (FASN) FATP FABP S-adenosylhomocysteine hydrolase (SAHH) Carboxylesterase (CES) OGA ELOVL Hormone-Sensitive Lipase (HSL)

製品番号	製品名	Target	研究分野	構造式

HY-14595

Biochanin A Maximum Cited Publications 15 Publications Verification 4-Methylgenistein; Olmelin	FAAH Autophagy Endogenous Metabolite	Neurological Disease Cancer
Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

HY-B0182

Carmofur 5+ Cited Publications HCFU	Nucleoside Antimetabolite/Analog SARS-CoV Virus Protease FAAH Ceramidase Glutathione Peroxidase	Infection Inflammation/Immunology Cancer
Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .

HY-14380

PF-3845 2 Publications Verification	FAAH Autophagy	Inflammation/Immunology Cancer
PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a K_i of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .

HY-119283

CAY10499 1 Publications Verification MAGL-IN-5	MAGL FAAH SARS-CoV Influenza Virus	Infection Metabolic Disease Inflammation/Immunology
CAY10499 (MAGL-IN-5) is a non-selective lipase inhibitor with IC₅₀ values of 144 nM and 14 nM for monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. Additionally, CAY10499 exhibits anti-inflammatory and antiviral activities .

HY-15250

JZL195 4 Publications Verification	FAAH MAGL Autophagy	Neurological Disease
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC₅₀s of 2 and 4 nM, respectively .

HY-110138

PDP-EA	FAAH	Others
PDP-EA is a compound that increases the amidohydrolase activity of FAAH (fatty acid amide hydrolase) .

HY-N2365

Macamide B 2 Publications Verification N-Benzylpalmitamide; N-Benzylhexadecanamide; Macamide 1	FAAH Autophagy	Others
Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).

HY-19740

BIA 10-2474 2 Publications Verification	FAAH Autophagy	Neurological Disease
BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (FAAH) with IC₅₀ values of 50 to 70mg/kg in various rat brain regions.

HY-18081

PF 750	FAAH Autophagy	Neurological Disease Metabolic Disease
PF 750 is a selective, covalent and brain-penetrant **fatty acid amide hydrolase (FAAH**) inhibitor. PF 750 covalently carbamylates FAAH's catalytic serine nucleophile to inactivate the enzyme .

HY-10865

LY2183240 3 Publications Verification	FAAH Autophagy	Neurological Disease
LY2183240 is a highly potent blocker of anandamide uptake (IC₅₀= 270 pM; K_i=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC₅₀ of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC₅₀s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .

HY-N7062

JNJ-1661010 Takeda-25	FAAH	Neurological Disease
JNJ-1661010 (Takeda-25) a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics .

HY-120961

Oleoyl ethyl amide N-Ethyloleamide	FAAH	Metabolic Disease
Oleoyl ethyl amide (N-Ethyloleamide) is a fatty acid amide hydrolase (FAAH) inhibitor. Oleoyl ethyl amide can counteract bladder overactivity .

HY-101457

JZP-430	MAGL	Metabolic Disease
JZP-430 is a potent, highly selective, irreversible inhibitor of *α/β-hydrolase* domain 6 (ABHD6) with an IC₅₀** of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .

HY-125967

AM 374	FAAH	Neurological Disease
AM 374 is an fatty acid amide hydrolase (FAAH) inhibitor. AM 374 inhibits amidase activity with an IC₅₀ value of 13 nM. AM 374 can be used for the research of neurological disease .

HY-120957

AMC Arachidonoyl Amide AMC-AA; 7-Amino-4-methyl coumarin-arachidonamide	Endogenous Metabolite	Metabolic Disease
AMC arachidonoyl amide (AMC-AA) is one of several fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its nominal endogenous substrate anandamide.2 Exposure of AMC-AA to FAAH activity results in the release of the fluorescent aminomethyl coumarin that absorbs at 360 nm and emits at 465 nm. This allows the fast and convenient measurement of FAAH activity using a simple cuvette or microplate fluorometer.

HY-103462

TC-F2	FAAH	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .

HY-121422

JZP-361	MAGL Histamine Receptor	Inflammation/Immunology
JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC₅₀ of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research .

HY-118158

FAAH/MAGL-IN-4	FAAH	Neurological Disease
FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC₅₀s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .

HY-164495

Sob-AM2	FAAH Thyroid Hormone Receptor	Inflammation/Immunology Endocrinology
Sob-AM2 is a potent substrate (K_m=1.3 μM) targeting fatty acid amide hydrolase (FAAH) expressed in the brain and has blood-brain barrier permeability. Sob-AM2 delivers high concentrations of Sobetirome (HY-14823) to the central nervous system with minimal peripheral systemic dose, thereby stimulating central thyroid hormone receptor β (TRβ). In addition, Sob-AM2 can prevent myelin and axon degeneration in experimental autoimmune encephalomyelitis (EAE) mice .

HY-152251

CB2R/FAAH modulator-1	Cannabinoid Receptor FAAH	Inflammation/Immunology
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K_is of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .

HY-W751418

N-Nervonoyl taurine (Z)-2-tetracos-15-enamidoethanesulfonic acid	FAAH	Neurological Disease
N-Nervonoyl taurine ((Z)-2-tetracos-15-enamidoethanesulfonic acid) is a fatty acid-taurine conjugate derived from nervonic acid. N-Nervonoyl taurine is a substrate of fatty acid amide hydrolase (FAAH) discovered during metabolite profiling .

HY-123863

SSR411298	FAAH	Neurological Disease
SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research .

HY-14595R

Biochanin A (Standard) Maximum Cited Publications 15 Publications Verification 4-Methylgenistein(Standard); Olmelin (Standard)	Reference Standards FAAH Autophagy Endogenous Metabolite	Neurological Disease Cancer
Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

HY-103337

N-Arachidonoylserotonin Arachidonyl serotonin; AA-5-HT	FAAH TRP Channel	Neurological Disease
N-Arachidonoylserotonin (Arachidonyl serotonin; AA-5-HT) is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ value of 1~12 µM. N-Arachidonoylserotonin acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels (IC₅₀=70~100 nM). N-Arachidonoylserotonin is analgesic in rodents .

HY-18080

SA 47	FAAH Autophagy	Metabolic Disease
SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate .

HY-111389

FAAH-IN-1	FAAH Autophagy	Metabolic Disease
FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC₅₀s of 145 nM and 650 nM for rat and human FAAH, respectively.

HY-N3033

N-Benzyllinolenamide 1 Publications Verification	FAAH Autophagy	Metabolic Disease
N-Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 41.8 μM .

HY-144738

Dual FAAH/sEH-IN-1	Epoxide Hydrolase FAAH	Inflammation/Immunology
Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC₅₀ values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase .

HY-32952

2-Fluoropyridine-5-boronic acid 6-Fluoropyridine-3-boronic acid	Drug Intermediate	Others
2-Fluoropyridine-5-boronic acid (6-Fluoropyridine-3-boronic acid) is a drug intermediate that can be used in the synthesis of fatty acid amide hydrolase inhibitors and pyrethroid derivatives .

HY-103461

FAAH-IN-6	FAAH	Neurological Disease
FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain .

HY-118210

PHOP	FAAH	Metabolic Disease
PHOP is a fatty acid amide hydrolase (FAAH) inhibitor used to assess inhibitory activity in a fluorometric assay. PHOP can determine FAAH activity by measuring the amount of 4-pyridin-1-ylbutyric acid released by the enzyme in rat brain microsomes. PHOP demonstrates potential as a FAAH inhibitor and can directly measure FAAH activity by reversed-phase HPLC and fluorescence detection, providing a basis for the development of new inhibitors.

HY-138693

ST4070	FAAH	Neurological Disease
ST4070 is a potent, orally active, and selective reversible fatty acid amide hydrolase (FAAH) inhibitor. ST4070 increases endocannabinoid (eCB) brain levels and counteracts neuropathic pain in animal models. ST4070 enhances the endogenous eCB tone in specific brain regions engaged in emotional control, and induces remarkable anxiolytic-like behaviours in rodents. ST4070 can be used for neuropathic pain and anxiety disorders research .

HY-126720

N-Lignoceroyl Taurine	Endogenous Metabolite	Metabolic Disease
N-Lignoceroyl Taurine is an arachidonoyl amino acid and taurine conjugate with a fatty acid that can be isolated from bovine brain. N-Lignoceroyl Taurine is one of several novel taurine-conjugated fatty acids discovered during mass spectrometry lipidomic analysis of the brain and spinal cord of wild-type and fatty acid amide hydrolase (FAAH) knockout mice. N-Lignoceroyl Taurine levels were 23-26-fold higher in FAAH ^-/- mice compared to wild-type mice, suggesting that FAAH utilizes N-Lignoceroyl Taurine as a substrate. However, in vitro experiments with purified FAAH showed that N-Lignoceroyl Taurine was hydrolyzed 2,000-fold slower in FAAH compared to oleoylethanolamide. N-Acyl Taurines with polyunsaturated acyl chains can activate members of the transient receptor potential (TRP) calcium channel family, including TRPV1 and TRPV4.

HY-124744

ASP 8477	FAAH	Neurological Disease
ASP 8477 is an orally active and selective fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀ values of 3.99, 1.65, and 57.3 nM for human FAAH-1, FAAH-1 (P129T), and FAAH-2, respectively. ASP 8477 has central nervous system activity and can be used in analgesia research .

HY-175816

5-HT6R/FAAH modulator 1	5-HT Receptor FAAH Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease
5-HT6R/FAAH modulator 1 is a selective serotonin 5-HT6 receptor ligand and the **fatty acid amide hydrolase (FAAH) enzyme inhibitor. 5-HT6R/FAAH modulator 1 shows a pK_i of 6.33 (5-HT6) and a pIC₅₀ valuesof 6.29 (FAAH). 5-HT6R/FAAH modulator 1 also slightly inhibits acetylcholinesterase (AChE) or butyrylcholinesterase (BChE) enzymes (pIC₅₀ = 5.12). 5-HT6R/FAAH modulator 1 can inhibit apoptosis and reduce ROS** levels. 5-HT6R/FAAH modulator 1 can be used for the research of neurological disease, such as Alzheimer’s disease (AD) .

HY-127023

Eicosapentaenoyl serotonin EPA-5-HT	Endogenous Metabolite FAAH Interleukin Related Tyrosine Hydroxylase	Metabolic Disease
Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses IL-17 release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms .

HY-10867

PF-622	FAAH	Metabolic Disease
PF-622 is a selective FAAH inhibitor, and can be used for study of analgesic and anxiolytic/antidepressant .

HY-139384

FAAH inhibitor 2	FAAH	Neurological Disease
FAAH inhibitor 2 (Compound 17b) is an irreversible fatty acid amide hydrolase (FAAH) inhibitor, with an IC₅₀ of 0.153 μM .

HY-158784

Arachidonoyl m-nitroaniline	FAAH	Others
Arachidonoyl m-Nitroaniline (AmNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity. Arachidonoyl m-Nitroaniline is a FAAH substrate .

HY-111199

JP83	FAAH	Neurological Disease
JP83 is an irreversible fatty acyl amide hydrolase (FAAH) inhibitor with an IC₅₀ of 1.6 nM in competitive activity-based protein profiling (ABPP) experiments .

HY-N2365R

Macamide B (Standard) N-Benzylpalmitamide (Standard); N-Benzylhexadecanamide (Standard); Macamide 1 (Standard)	Reference Standards FAAH Autophagy	Others
Macamide B (Standard) is the analytical standard of Macamide B. This product is intended for research and analytical applications. Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH).

HY-146341

FAAH-IN-5	FAAH MAGL	Neurological Disease
FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

HY-146342

FAAH/MAGL-IN-3	FAAH MAGL	Neurological Disease
FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC₅₀ values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .

HY-N2512R

1-Monomyristin (Standard)	Reference Standards FAAH Bacterial Fungal Endogenous Metabolite Autophagy	Infection
1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC50=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC50=18 μM). 1-Monomyristin shows antibacterial activity against Staphylococcus aureus and Aggregatibacter actinomycetemcomitans and also antifungal activity against Candida albicans .

HY-B0182R

Carmofur (Standard) HCFU (Standard)	Reference Standards Nucleoside Antimetabolite/Analog SARS-CoV Virus Protease FAAH Ceramidase Glutathione Peroxidase	Infection Inflammation/Immunology Cancer
Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) .

HY-N15826

RBM1-151	Fluorescent Dye Ceramidase	Cancer
RBM1-151, a 1-deoxy derivative and vinilog of RBM14-C12 (HY-150163), as a fluorogenic substrate of Amidases (HY-P2736) (E_x/E_m). RBM1-151 is hydrolyzed by acid ceramidase (AC) (( ^appK_m = 7.0 μM; ^appV_max = 99.3 nM/min), N-acylethanolamine-hydrolyzing acid amidase ( ^appK_m = 0.73 μM; ^appV_max = 0.24 nM/min), and fatty Acid amide hydrolase (FAAH) ( ^appK_m = 3.6 μM; ^appV_max = 7.6 nM/min) but not by other ceramidases. RBM1-151 is applicable for basic biological studies of lipid amidase function, as well as potential diagnostic/prognostic evaluations of diseases involving dysregulated AC, NAAA, or FAAH (Farber disease, cancer) .

HY-U00240

SA72	FAAH Autophagy	Neurological Disease
SA72 is a highly selective fatty acid amide hydrolase (FAAH) inhibitor.

HY-W479534

Decanoyl m-Nitroaniline DemNA	Biochemical Assay Reagents	Others
Decanoyl m-Nitroaniline (DemNA) is a nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity (Ab = 410 nm).

HY-161965

MK-3168 (12C)	FAAH	Neurological Disease
MK-3168 (12C) is a FAAH inhibitor with IC₅₀ values of 1.0, 5.5, 1.7 nM for human, rhesus, rat, respectively. MK-3168 shows good brain uptake and FAAH-specific signal. ¹¹C MK-3168 can be used as FAAH PET tracer .

HY-120300

UCM710	Cannabinoid Receptor	Metabolic Disease
UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase .

製品番号	製品名	Type

HY-W479534

Decanoyl m-Nitroaniline DemNA	蛍光色素
Decanoyl m-Nitroaniline (DemNA) is a nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity (Ab = 410 nm).

HY-120971

N-Decanoyl p-Nitroaniline

DepNA

蛍光色素

N-Decanoyl p-nitroaniline (DepNA) is one of several nitroaniline fatty acid amides which can be used to measure fatty acid amide hydrolase (FAAH) activity.1 FAAH is a relatively unselective enzyme in that it accepts a variety of amide head groups other than the ethanolamine of its endogenous substrate anandamide (AEA). It also will hydrolyze fatty acid amides with fewer carbons and fewer double bonds than arachidonate. Exposure of DepNA to FAAH activity results in the release of the yellow colorimetric dye p-nitroaniline (ε=13,500 at 410 nm). This allows the fast and convenient measurement of FAAH activity using a 96 well plate spectrophotometer.

製品番号	製品名		Classification

HY-184029

PF-7845yne		Alkynes
PF-7845yne is a clickable analogue of PF-7845. PF-7845yne serves as a pharmacological probe to investigate effects of targeting the FAAH-anandamide pathway .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: